Comparative Study of Intraoperative MRI-guided vs. Conventional Glioma Surgery
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01394692 |
|
Recruitment Status :
Completed
First Posted : July 14, 2011
Results First Posted : November 28, 2012
Last Update Posted : November 28, 2012
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Excision to the maximum possible extent marks the first step of glioma surgery. Depending on tumour histology, adjuvant treatment consists of radio- and/or chemotherapy. Multi-centre studies have shown that the presence of residual tumour according to MRI-criteria is a prognostic factor in this incurable condition.
In order to improve the extent of resection, several methods, in particular intraoperative imaging techniques, have become available to demonstrate already during surgery whether the goal of surgery has been achieved. The intraoperative MRI devices currently available differ in their magnetic field strengths and image resolution, but also in their amount of interference with the surgical workflow.
Prospective, high-class evidence data to promote the use of intraoperative MRI in glioma surgery are lacking. To assess whether the rate of radiologically complete tumour resections can be improved by using intraoperative MRI-guidance, we designed this prospective, randomized trial. We hypothesized that the extent of resection that can be achieved using an intraoperative MRI is greater than that of conventional microsurgical tumor resection.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Glioma | Procedure: intraoperative MRI-guided tumor resection Procedure: standard microsurgery | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 58 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Resection Control of Primary Brain Tumours Using a Low-Field Intraoperative MRI |
| Study Start Date : | October 2007 |
| Actual Primary Completion Date : | July 2010 |
| Actual Study Completion Date : | January 2011 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: intraoperative MRI
tumor resection with intraoperative MRI-guidance
|
Procedure: intraoperative MRI-guided tumor resection
tumor resection with the use of an intraoperative MRI
Other Name: PoleStar-N20 intraoperative MRI |
|
Active Comparator: conventional group
standard microsurgical tumor resection
|
Procedure: standard microsurgery
microsurgical tumor resection |
- Extent of Resection [ Time Frame: 72 hours ]Number of patients with contrast-enhancing glioma in whom a complete excision of the tumor according to postoperative high-field MRI within 72 hours is achieved
- Progression-free Survival [ Time Frame: 6 months ]Progression-free survival (radiological and/or clinical progression) at 6 months following surgery
- Volumetric Assessment [ Time Frame: 72 hours ]Volumetric assessment of the extent of resection on early (within 72h) postoperative MRI
- Neurological Deficit [ Time Frame: 7 days ]Assessment of new postoperative deficits following tumor surgery
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- known or suspected contrast-enhancing glioma (primary and recurrent)
- location of the tumor permits intended gross-total resection
Exclusion Criteria:
- tumor location prohibits or questions gross-total resection
- contraindications to undergo MRI examinations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01394692
| Germany | |
| Department of Neurosurgery, Goethe-University | |
| Frankfurt, Germany, 60528 | |
| Principal Investigator: | Christian Senft, M.D. | Goethe University | |
| Study Director: | Volker Seifert, M.D. | Goethe University |
| Responsible Party: | Christian Senft, Neurosurgeon, Goethe University |
| ClinicalTrials.gov Identifier: | NCT01394692 |
| Other Study ID Numbers: |
JWG-EK 239/07 |
| First Posted: | July 14, 2011 Key Record Dates |
| Results First Posted: | November 28, 2012 |
| Last Update Posted: | November 28, 2012 |
| Last Verified: | October 2012 |
|
intraoperative MRI glioma surgery extent of resection |
|
Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue |

